Print PDF

Sheppard Mullin Advises $200M Life Sciences SPAC IPO


Sheppard Mullin advised Valuence Merger Corp. I (“Valuence”) in connection with the initial public offering of 20,000,000 units of Valuence Merger Corp. I, for gross proceeds of $200 million. The units were listed on the Nasdaq Capital Market under the symbol “VMCAU.” Valuence Merger Corp. I is a newly incorporated special purpose acquisition company (SPAC) whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The focus of Valuence is to identify, merge with, and partner with a business in Asia (excluding China, Hong Kong, and Macau) with a particular focus on breakthrough technology in life sciences and/or sustainable technology.

The Sheppard Mullin deal team included partners Paul Kim in Seoul, Richard Friedman, Soyun Park and Niya Tang in New York, and Jason Schendel in Silicon Valley; special counsel Sean Reid in New York; and associate Emily Mastoloni in New York.

Click here to read the press release.


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.